Treatment of primary sclerosing cholangitis in children
|
摘要
Primary sclerosing cholangitis(PSC) is a rare disease of stricturing and destruction of the biliary tree with a complex genetic and environmental etiology.Most patients have co-occurring inflammatory bowel disease. Children generally present with uncomplicated disease, but undergo a variable progression to endstage liver disease. Within ten years of diagnosis, 50% of children will develop clinical complications including 30% requiring liver transplantation.Cholangiocarcinoma is a rare but serious complication affecting 1% of children.Ursodeoxycholic acid and oral vancomycin therapy used widely in children as medical therapy, and may be effective in a subset of patients. Gamma glutamyltransferase is a potential surrogate endpoint for disease activity, with improved survival in patients who achieve a normal value. Endoscopic retrograde cholangiopancreatography is a necessary adjunct to medical therapy to evaluate mass lesions or dominant strictures for malignancy, and also to relieve biliary obstruction. Liver transplantation remains the only option for patients who progress to end-stage liver disease. We review special considerations for patients before and after transplant, and in patients with inflammatory bowel disease. There is presently no published treatment algorithm or guideline for the management of children with PSC. We review the evidence for drug efficacy, dosing, duration of therapy, and treatment targets in PSC, and provide a framework for endoscopic and medical management of this complex problem.
Primary sclerosing cholangitis(PSC) is a rare disease of stricturing and destruction of the biliary tree with a complex genetic and environmental etiology.Most patients have co-occurring inflammatory bowel disease. Children generally present with uncomplicated disease, but undergo a variable progression to endstage liver disease. Within ten years of diagnosis, 50% of children will develop clinical complications including 30% requiring liver transplantation.Cholangiocarcinoma is a rare but serious complication affecting 1% of children.Ursodeoxycholic acid and oral vancomycin therapy used widely in children as medical therapy, and may be effective in a subset of patients. Gamma glutamyltransferase is a potential surrogate endpoint for disease activity, with improved survival in patients who achieve a normal value. Endoscopic retrograde cholangiopancreatography is a necessary adjunct to medical therapy to evaluate mass lesions or dominant strictures for malignancy, and also to relieve biliary obstruction. Liver transplantation remains the only option for patients who progress to end-stage liver disease. We review special considerations for patients before and after transplant, and in patients with inflammatory bowel disease. There is presently no published treatment algorithm or guideline for the management of children with PSC. We review the evidence for drug efficacy, dosing, duration of therapy, and treatment targets in PSC, and provide a framework for endoscopic and medical management of this complex problem.
Primary sclerosing cholangitis(PSC) is a rare disease of stricturing and destruction of the biliary tree with a complex genetic and environmental etiology.Most patients have co-occurring inflammatory bowel disease. Children generally present with uncomplicated disease, but undergo a variable progression to endstage liver disease. Within ten years of diagnosis, 50% of children will develop clinical complications including 30% requiring liver transplantation.Cholangiocarcinoma is a rare but serious complication affecting 1% of children.Ursodeoxycholic acid and oral vancomycin therapy used widely in children as medical therapy, and may be effective in a subset of patients. Gamma glutamyltransferase is a potential surrogate endpoint for disease activity, with improved survival in patients who achieve a normal value. Endoscopic retrograde cholangiopancreatography is a necessary adjunct to medical therapy to evaluate mass lesions or dominant strictures for malignancy, and also to relieve biliary obstruction. Liver transplantation remains the only option for patients who progress to end-stage liver disease. We review special considerations for patients before and after transplant, and in patients with inflammatory bowel disease. There is presently no published treatment algorithm or guideline for the management of children with PSC. We review the evidence for drug efficacy, dosing, duration of therapy, and treatment targets in PSC, and provide a framework for endoscopic and medical management of this complex problem.
引文
1 Deneau M,Jensen MK,Holmen J,Williams MS,Book LS,Guthery SL.Primary sclerosing cholangitis,autoimmune hepatitis,and overlap in Utah children:epidemiology and natural history.Hepatology 2013;58:1392-1400[PMID:23686586 DOI:10.1002/hep.26454]
2 Deneau MR,El-Matary W,Valentino PL,Abdou R,Alqoaer K,Amin M,Amir AZ,Auth M,Bazerbachi F,Broderick A,Chan A,Cotter J,Doan S,El-Youssef M,Ferrari F,Furuya KN,Gottrand M,Gottrand F,Gupta N,Homan M,Kamath BM,Kim KM,Kolho KL,Konidari A,Koot B,Iorio R,Ledder O,Mack C,Martinez M,Miloh T,Mohan P,O'Cathain N,Papadopoulou A,Ricciuto A,Saubermann L,Sathya P,Shteyer E,Smolka V,Tanaka A,Varier R,Venkat V,Vitola B,Vos MB,Woynarowski M,Yap J,Jensen MK.The natural history of primary sclerosing cholangitis in 781 children:A multicenter,international collaboration.Hepatology 2017;66:518-527[PMID:28390159 DOI:10.1002/hep.29204]
3 Dyson JK,Webb G,Hirschfield GM,Lohse A,Beuers U,Lindor K,Jones DE.Unmet clinical need in autoimmune liver diseases.J Hepatol 2015;62:208-218[PMID:25234946 DOI:10.1016/j.jhep.2014.09.010]
4 Damman JL,Rodriguez EA,Ali AH,Buness CW,Cox KL,Carey EJ,Lindor KD.Review article:the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis.Aliment Pharmacol Ther 2018;47:886-895[PMID:29411404 DOI:10.1111/apt.14540]
5 Smit JJ,Schinkel AH,Oude Elferink RP,Groen AK,Wagenaar E,van Deemter L,Mol CA,Ottenhoff R,van der Lugt NM,van Roon MA.Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease.Cell 1993;75:451-462[PMID:8106172]
6 Hohenester S,Wenniger LM,Paulusma CC,van Vliet SJ,Jefferson DM,Elferink RP,Beuers U.A biliary HCO3-umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes.Hepatology 2012;55:173-183[PMID:21932391 DOI:10.1002/hep.24691]
7 Fickert P,Hirschfield GM,Denk G,Marschall HU,Altorjay I,F?rkkil?M,Schramm C,Spengler U,Chapman R,Bergquist A,Schrumpf E,Nevens F,Trivedi P,Reiter FP,Tornai I,Halilbasic E,Greinwald R,Pr?ls M,Manns MP,Trauner M;European PSC norUDCA Study Group.norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.J Hepatol 2017;67:549-558[PMID:28529147DOI:10.1016/j.jhep.2017.05.009]
8 Fernandez-Barrena MG,Barcena-Varela M,Banales JM.New evidence supporting the biliary bicarbonate umbrella theory.Clin Res Hepatol Gastroenterol 2017;41:126-128[PMID:27818187 DOI:10.1016/j.clinre.2016.09.004]
9 Galle PR,Theilmann L,Raedsch R,Otto G,Stiehl A.Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes.Hepatology 1990;12:486-491[PMID:2401454]
10 Stiehl A,Rudolph G,Raedsch R,M?ller B,Hopf U,Lotterer E,Bircher J,F?lsch U,Klaus J,Endele R.Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis.Hepatology 1990;12:492-497[PMID:2401455]
11 Calmus Y,Gane P,Rouger P,Poupon R.Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis:effect of ursodeoxycholic acid.Hepatology 1990;11:12-15[PMID:2403961]
12 Lindor KD,Dickson ER,Baldus WP,Jorgensen RA,Ludwig J,Murtaugh PA,Harrison JM,Wiesner RH,Anderson ML,Lange SM.Ursodeoxycholic acid in the treatment of primary biliary cirrhosis.Gastroenterology 1994;106:1284-1290[PMID:8174890]
13 Lindor KD,Therneau TM,Jorgensen RA,Malinchoc M,Dickson ER.Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis.Gastroenterology 1996;110:1515-1518[PMID:8613058]
14 Lindor KD.Ursodiol for primary sclerosing cholangitis.Mayo Primary Sclerosing CholangitisUrsodeoxycholic Acid Study Group.N Engl J Med 1997;336:691-695[PMID:9041099 DOI:10.1056/NEJM199703063361003]
15 Cullen SN,Rust C,Fleming K,Edwards C,Beuers U,Chapman RW.High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective.J Hepatol 2008;48:792-800[PMID:18314215 DOI:10.1016/j.jhep.2007.12.023]
16 Olsson R,Boberg KM,de Muckadell OS,Lindgren S,Hultcrantz R,Folvik G,Bell H,Gangs?yKristiansen M,Matre J,Rydning A,Wikman O,Danielsson A,Sandberg-Gertzén H,Ung KA,Eriksson A,L??f L,Prytz H,Marschall HU,BrooméU.High-dose ursodeoxycholic acid in primary sclerosing cholangitis:a 5-year multicenter,randomized,controlled study.Gastroenterology 2005;129:1464-1472[PMID:16285948 DOI:10.1053/j.gastro.2005.08.017]
17 Harnois DM,Angulo P,Jorgensen RA,Larusso NF,Lindor KD.High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis.Am J Gastroenterol 2001;96:1558-1562[PMID:11374699 DOI:10.1111/j.1572-0241.2001.03777.x]
18 Lindor KD,Kowdley KV,Luketic VA,Harrison ME,McCashland T,Befeler AS,Harnois D,Jorgensen R,Petz J,Keach J,Mooney J,Sargeant C,Braaten J,Bernard T,King D,Miceli E,Schmoll J,Hoskin T,Thapa P,Enders F.High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.Hepatology 2009;50:808-814[PMID:19585548 DOI:10.1002/hep.23082]
19 Chapman MH,Webster GJ,Bannoo S,Johnson GJ,Wittmann J,Pereira SP.Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis:a 25-year single-centre experience.Eur J Gastroenterol Hepatol 2012;24:1051-1058[PMID:22653260 DOI:10.1097/MEG.0b013e3283554bbf]
20 Chapman R,Fevery J,Kalloo A,Nagorney DM,Boberg KM,Shneider B,Gores GJ;American Association for the Study of Liver Diseases.Diagnosis and management of primary sclerosing cholangitis.Hepatology 2010;51:660-678[PMID:20101749 DOI:10.1002/hep.23294]
21 Ponsioen CY,Lindor KD,Mehta R,Dimick-Santos L.Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis.Hepatology 2018;68:1174-1188[PMID:29574971 DOI:10.1002/hep.29882]
22 Wunsch E,Trottier J,Milkiewicz M,Raszeja-Wyszomirska J,Hirschfield GM,Barbier O,Milkiewicz P.Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis.Hepatology 2014;60:931-940[PMID:24519384 DOI:10.1002/hep.27074]
23 Tabibian JH,Lindor KD.Ursodeoxycholic acid in primary sclerosing cholangitis:if withdrawal is bad,then administration is good(right?).Hepatology 2014;60:785-788[PMID:24752961 DOI:10.1002/hep.27180]
24 Deneau MR,Mack C,Abdou R,Amin M,Amir A,Auth M,Bazerbachi F,Marie Broderick A,Chan A,DiGuglielmo M,El-Matary W,El-Youssef M,Ferrari F,Furuya KN,Gottrand F,Gupta N,Homan M,Jensen MK,Kamath BM,Mo Kim K,Kolho KL,Konidari A,Koot B,Iorio R,Martinez M,Mohan P,Palle S,Papadopoulou A,Ricciuto A,Saubermann L,Sathya P,Shteyer E,Smolka V,Tanaka A,Valentino PL,Varier R,Venkat V,Vitola B,Vos MB,Woynarowski M,Yap J,Miloh T.Gamma Glutamyltransferase Reduction Is Associated With Favorable Outcomes in Pediatric Primary Sclerosing Cholangitis.Hepatol Commun 2018;2:1369-1378[PMID:30411083 DOI:10.1002/hep4.1251]
25 Lindstr?m L,Hultcrantz R,Boberg KM,Friis-Liby I,Bergquist A.Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis.Clin Gastroenterol Hepatol 2013;11:841-846[PMID:23353641 DOI:10.1016/j.cgh.2012.12.032]
26 Al Mamari S,Djordjevic J,Halliday JS,Chapman RW.Improvement of serum alkaline phosphatase to<1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis.J Hepatol 2013;58:329-334[PMID:23085647 DOI:10.1016/j.jhep.2012.10.013]
27 Rupp C,R?ssler A,Halibasic E,Sauer P,Weiss KH,Friedrich K,Wannhoff A,Stiehl A,Stremmel W,Trauner M,Gotthardt DN.Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis,independent of dominant stenosis.Aliment Pharmacol Ther 2014;40:1292-1301[PMID:25316001 DOI:10.1111/apt.12979]
28 de Vries EM,Wang J,Leeflang MM,Boonstra K,Weersma RK,Beuers UH,Geskus RB,Ponsioen CY.Alkaline phosphatase at diagnosis of primary sclerosing cholangitis and 1 year later:evaluation of prognostic value.Liver Int 2016;36:1867-1875[PMID:26945698 DOI:10.1111/liv.13110]
29 Stanich PP,Bj?rnsson E,Gossard AA,Enders F,Jorgensen R,Lindor KD.Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis.Dig Liver Dis 2011;43:309-313[PMID:21251891 DOI:10.1016/j.dld.2010.12.008]
30 Imam MH,Sinakos E,Gossard AA,Kowdley KV,Luketic VA,Edwyn Harrison M,McCashland T,Befeler AS,Harnois D,Jorgensen R,Petz J,Keach J,DeCook AC,Enders F,Lindor KD.High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis.Aliment Pharmacol Ther 2011;34:1185-1192[PMID:21957881 DOI:10.1111/j.1365-2036.2011.04863.x]
31 Gilger MA,Gann ME,Opekun AR,Gleason WA.Efficacy of ursodeoxycholic acid in the treatment of primary sclerosing cholangitis in children.J Pediatr Gastroenterol Nutr 2000;31:136-141[PMID:10941964]
32 Black D MC,Kerkar N,Miloh T,Sundaram S,Anand R,Gupta A,Alonso E,Arnon R,Bulut P,Karpen S,Lin C,Rosenthal P,Ryan M,Squires R,Valentino P,Schneider B.Initial Results of the WUPPSCStudy-Prospective Multicenter Withdrawal of Ursodeoxycholic Acid in Pediatric Primary Sclerosing Cholangitis.Gastroenterology 2018;154:S1209
33 Lichtman SN,Sartor RB,Keku J,Schwab JH.Hepatic inflammation in rats with experimental small intestinal bacterial overgrowth.Gastroenterology 1990;98:414-423[PMID:2295397]
34 Rossen NG,Fuentes S,Boonstra K,D'Haens GR,Heilig HG,Zoetendal EG,de Vos WM,Ponsioen CY.The mucosa-associated microbiota of PSC patients is characterized by low diversity and low abundance of uncultured Clostridiales II.J Crohns Colitis 2015;9:342-348[PMID:25547975 DOI:10.1093/ecco-jcc/jju023]
35 Grant AJ,Lalor PF,Hübscher SG,Briskin M,Adams DH.MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium(MAdCAM-1 in chronic inflammatory liver disease).Hepatology 2001;33:1065-1072[PMID:11343233 DOI:10.1053/jhep.2001.24231]
36 Kevans D,Tyler AD,Holm K,J?rgensen KK,Vatn MH,Karlsen TH,Kaplan GG,Eksteen B,Gevers D,Hov JR,Silverberg MS.Characterization of Intestinal Microbiota in Ulcerative Colitis Patients with and without Primary Sclerosing Cholangitis.J Crohns Colitis 2016;10:330-337[PMID:26526357 DOI:10.1093/ecco-jcc/jjv204]
37 Kummen M,Holm K,Anmarkrud JA,Nyg?rd S,Vesterhus M,H?ivik ML,Tr?seid M,Marschall HU,Schrumpf E,Moum B,R?sj?H,Aukrust P,Karlsen TH,Hov JR.The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls.Gut 2017;66:611-619[PMID:26887816 DOI:10.1136/gutjnl-2015-310500]
38 Sabino J,Vieira-Silva S,Machiels K,Joossens M,Falony G,Ballet V,Ferrante M,Van Assche G,Van der Merwe S,Vermeire S,Raes J.Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD.Gut 2016;65:1681-1689[PMID:27207975 DOI:10.1136/gutjnl-2015-311004]
39 Iwasawa K,Suda W,Tsunoda T,Oikawa-Kawamoto M,Umetsu S,Takayasu L,Inui A,Fujisawa T,Morita H,Sogo T,Hattori M.Dysbiosis of the salivary microbiota in pediatric-onset primary sclerosing cholangitis and its potential as a biomarker.Sci Rep 2018;8:5480[PMID:29615776 DOI:10.1038/s41598-018-23870-w]
40 Tabibian JH,Gossard A,El-Youssef M,Eaton JE,Petz J,Jorgensen R,Enders FB,Tabibian A,Lindor KD.Prospective Clinical Trial of Rifaximin Therapy for Patients With Primary Sclerosing Cholangitis.Am J Ther 2017;24:e56-e63[PMID:24914504 DOI:10.1097/MJT.0000000000000102]
41 Mistilis SP,Skyring AP,Goulston SJ.Effect of long-term tetracycline therapy,steroid therapy and colectomy in pericholangitis associated with ulcerative colitis.Australas Ann Med 1965;14:286-294[PMID:5861251]
42 Silveira MG,Torok NJ,Gossard AA,Keach JC,Jorgensen RA,Petz JL,Lindor KD.Minocycline in the treatment of patients with primary sclerosing cholangitis:results of a pilot study.Am J Gastroenterol 2009;104:83-88[PMID:19098854 DOI:10.1038/ajg.2008.14]
43 F?rkkil?M,Karvonen AL,Nurmi H,Nuutinen H,Taavitsainen M,Pikkarainen P,K?rkk?inen P.Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis:a randomized placebocontrolled trial.Hepatology 2004;40:1379-1386[PMID:15565569 DOI:10.1002/hep.20457]
44 Tabibian JH,Weeding E,Jorgensen RA,Petz JL,Keach JC,Talwalkar JA,Lindor KD.Randomised clinical trial:vancomycin or metronidazole in patients with primary sclerosing cholangitis-a pilot study.Aliment Pharmacol Ther 2013;37:604-612[PMID:23384404 DOI:10.1111/apt.12232]
45 Davies YK,Cox KM,Abdullah BA,Safta A,Terry AB,Cox KL.Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin:an immunomodulating antibiotic.J Pediatr Gastroenterol Nutr 2008;47:61-67[PMID:18607270 DOI:10.1097/MPG.0b013e31816fee95]
46 Moellering RC.Vancomycin:a 50-year reassessment.Clin Infect Dis 2006;42 Suppl 1:S3-S4[PMID:16323117 DOI:10.1086/491708]
47 Abarbanel DN,Seki SM,Davies Y,Marlen N,Benavides JA,Cox K,Nadeau KC,Cox KL.Immunomodulatory effect of vancomycin on Treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis.J Clin Immunol 2013;33:397-406[PMID:23054338 DOI:10.1007/s10875-012-9801-1]
48 Deneau MR,Amin M,Amir AZ,Auth M,Bazerbachi F,Broderick A,El-Youssef M,Ferrari F,Furuya KN,Gottrand F,Gupta N,Homan M,Kamath BM,Lin H,Mo Kim K,Kolho KL,Konidari A,Koot B,Iorio R,Jensen MK,Mack C,Martinez M,Ricciuto A,Smolka V,Tanaka A,Valentino PL,Venkat V,Vitola B,Vos MB,Woynarowski M,Yap J,Miloh T.Variability in Diagnostic and Therapeutic Strategies for Pediatric Primary Sclerosing Cholangitis between Centers in the Pediatric PSC Consortium.Hepatology 2018;68
49 Rahimpour S,Nasiri-Toosi M,Khalili H,Ebrahimi-Daryani N,Nouri-Taromlou MK,Azizi Z.A Triple Blinded,Randomized,Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis:a Pilot Study.J Gastrointestin Liver Dis 2016;25:457-464[PMID:27981301 DOI:10.15403/jgld.2014.1121.254.rah]
50 Valentino PL,Wiggins S,Harney S,Raza R,Lee CK,Jonas MM.The Natural History of Primary Sclerosing Cholangitis in Children:A Large Single-Center Longitudinal Cohort Study.J Pediatr Gastroenterol Nutr 2016;63:603-609[PMID:27504812 DOI:10.1097/MPG.0000000000001368]
51 Karlsen TH,Folseraas T,Thorburn D,Vesterhus M.Primary sclerosing cholangitis-a comprehensive review.J Hepatol 2017;67:1298-1323[PMID:28802875 DOI:10.1016/j.jhep.2017.07.022]
52 Ji SG,Juran BD,Mucha S,Folseraas T,Jostins L,Melum E,Kumasaka N,Atkinson EJ,Schlicht EM,Liu JZ,Shah T,Gutierrez-Achury J,Boberg KM,Bergquist A,Vermeire S,Eksteen B,Durie PR,Farkkila M,Müller T,Schramm C,Sterneck M,Weismüller TJ,Gotthardt DN,Ellinghaus D,Braun F,Teufel A,Laudes M,Lieb W,Jacobs G,Beuers U,Weersma RK,Wijmenga C,Marschall HU,Milkiewicz P,Pares A,Kontula K,Chazouillères O,Invernizzi P,Goode E,Spiess K,Moore C,Sambrook J,Ouwehand WH,Roberts DJ,Danesh J,Floreani A,Gulamhusein AF,Eaton JE,Schreiber S,Coltescu C,Bowlus CL,Luketic VA,Odin JA,Chopra KB,Kowdley KV,Chalasani N,Manns MP,Srivastava B,Mells G,Sandford RN,Alexander G,Gaffney DJ,Chapman RW,Hirschfield GM,de Andrade M;UK-PSCConsortium;International IBD Genetics Consortium;International PSC Study Group,Rushbrook SM,Franke A,Karlsen TH,Lazaridis KN,Anderson CA.Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease.Nat Genet 2017;49:269-273[PMID:27992413 DOI:10.1038/ng.3745]
53 Liu JZ,Hov JR,Folseraas T,Ellinghaus E,Rushbrook SM,Doncheva NT,Andreassen OA,Weersma RK,Weismüller TJ,Eksteen B,Invernizzi P,Hirschfield GM,Gotthardt DN,Pares A,Ellinghaus D,Shah T,Juran BD,Milkiewicz P,Rust C,Schramm C,Müller T,Srivastava B,Dalekos G,N?then MM,Herms S,Winkelmann J,Mitrovic M,Braun F,Ponsioen CY,Croucher PJ,Sterneck M,Teufel A,Mason AL,Saarela J,Leppa V,Dorfman R,Alvaro D,Floreani A,Onengut-Gumuscu S,Rich SS,Thompson WK,Schork AJ,N?ss S,Thomsen I,Mayr G,K?nig IR,Hveem K,Cleynen I,Gutierrez-Achury J,Rica?oPonce I,van Heel D,Bj?rnsson E,Sandford RN,Durie PR,Melum E,Vatn MH,Silverberg MS,Duerr RH,Padyukov L,Brand S,Sans M,Annese V,Achkar JP,Boberg KM,Marschall HU,Chazouillères O,Bowlus CL,Wijmenga C,Schrumpf E,Vermeire S,Albrecht M;UK-PSCSC Consortium,Rioux JD,Alexander G,Bergquist A,Cho J,Schreiber S,Manns MP,F?rkkil?M,Dale AM,Chapman RW,Lazaridis KN;International PSC Study Group,Franke A,Anderson CA,Karlsen TH;International IBDGenetics Consortium.Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis.Nat Genet 2013;45:670-675[PMID:23603763 DOI:10.1038/ng.2616]
54 Folseraas T,Melum E,Rausch P,Juran BD,Ellinghaus E,Shiryaev A,Laerdahl JK,Ellinghaus D,Schramm C,Weismüller TJ,Gotthardt DN,Hov JR,Clausen OP,Weersma RK,Janse M,Boberg KM,Bj?rnsson E,Marschall HU,Cleynen I,Rosenstiel P,Holm K,Teufel A,Rust C,Gieger C,Wichmann HE,Bergquist A,Ryu E,Ponsioen CY,Runz H,Sterneck M,Vermeire S,Beuers U,Wijmenga C,Schrumpf E,Manns MP,Lazaridis KN,Schreiber S,Baines JF,Franke A,Karlsen TH.Extended analysis of a genomewide association study in primary sclerosing cholangitis detects multiple novel risk loci.J Hepatol 2012;57:366-375[PMID:22521342 DOI:10.1016/j.jhep.2012.03.031]
55 Tse CS,Loftus EV,Raffals LE,Gossard AA,Lightner AL.Effects of vedolizumab,adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease.Aliment Pharmacol Ther 2018;48:190-195[PMID:29808485 DOI:10.1111/apt.14829]
56 Bj?rnsson E,Cederborg A,Akvist A,Simren M,Stotzer PO,Bjarnason I.Intestinal permeability and bacterial growth of the small bowel in patients with primary sclerosing cholangitis.Scand J Gastroenterol2005;40:1090-1094[PMID:16211716]
57 Tornai T,Palyu E,Vitalis Z,Tornai I,Tornai D,Antal-Szalmas P,Norman GL,Shums Z,Veres G,Dezsofi A,Par G,Par A,Orosz P,Szalay F,Lakatos PL,Papp M.Gut barrier failure biomarkers are associated with poor disease outcome in patients with primary sclerosing cholangitis.World JGastroenterol 2017;23:5412-5421[PMID:28839442 DOI:10.3748/wjg.v23.i29.5412]
58 Lichtman SN,Keku J,Schwab JH,Sartor RB.Hepatic injury associated with small bowel bacterial overgrowth in rats is prevented by metronidazole and tetracycline.Gastroenterology 1991;100:513-519[PMID:1985047]
59 Grant AJ,Lalor PF,Salmi M,Jalkanen S,Adams DH.Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease.Lancet 2002;359:150-157[PMID:11809275 DOI:10.1016/S0140-6736(02)07374-9]
60 Zweers SJ,Shiryaev A,Komuta M,Vesterhus M,Hov JR,Perugorria MJ,de Waart DR,Chang JC,Tol S,Te Velde AA,de Jonge WJ,Banales JM,Roskams T,Beuers U,Karlsen TH,Jansen PL,Schaap FG.Elevated interleukin-8 in bile of patients with primary sclerosing cholangitis.Liver Int 2016;36:1370-1377[PMID:26866350 DOI:10.1111/liv.13092]
61 Liu R,Zhao R,Zhou X,Liang X,Campbell DJ,Zhang X,Zhang L,Shi R,Wang G,Pandak WM,Sirica AE,Hylemon PB,Zhou H.Conjugated bile acids promote cholangiocarcinoma cell invasive growth through activation of sphingosine 1-phosphate receptor 2.Hepatology 2014;60:908-918[PMID:24700501 DOI:10.1002/hep.27085]
62 Sokol H,Cosnes J,Chazouilleres O,Beaugerie L,Tiret E,Poupon R,Seksik P.Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis.World JGastroenterol 2008;14:3497-3503[PMID:18567077]
63 Mendes FD,Levy C,Enders FB,Loftus EV,Angulo P,Lindor KD.Abnormal hepatic biochemistries in patients with inflammatory bowel disease.Am J Gastroenterol 2007;102:344-350[PMID:17100965DOI:10.1111/j.1572-0241.2006.00947.x]
64 Shiau H,Ihekweazu FD,Amin M,Fofanova T,Miloh T,Kellermayer R.Unique Inflammatory Bowel Disease Phenotype of Pediatric Primary Sclerosing Cholangitis:A Single-Center Study.J Pediatr Gastroenterol Nutr 2017;65:404-409[PMID:28141677 DOI:10.1097/MPG.0000000000001531]
65 Stockbrügger RW,Olsson R,Jaup B,Jensen J.Forty-six patients with primary sclerosing cholangitis:radiological bile duct changes in relationship to clinical course and concomitant inflammatory bowel disease.Hepatogastroenterology 1988;35:289-294[PMID:3215625]
66 Nordenvall C,Olén O,Nilsson PJ,von Seth E,Ekbom A,Bottai M,Myrelid P,Bergquist A.Colectomy prior to diagnosis of primary sclerosing cholangitis is associated with improved prognosis in a nationwide cohort study of 2594 PSC-IBD patients.Aliment Pharmacol Ther 2018;47:238-245[PMID:29064110DOI:10.1111/apt.14393]
67 Gulamhusein AF,Eaton JE,Tabibian JH,Atkinson EJ,Juran BD,Lazaridis KN.Duration of Inflammatory Bowel Disease Is Associated With Increased Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis and IBD.Am J Gastroenterol 2016;111:705-711[PMID:27002801 DOI:10.1038/ajg.2016.55]
68 de Vries AB,Janse M,Blokzijl H,Weersma RK.Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis.World J Gastroenterol 2015;21:1956-1971[PMID:25684965 DOI:10.3748/wjg.v21.i6.1956]
69 Mosli M,Croome K,Qumosani K,Al-Judaibi B,Beaton M,Marotta P,Chandok N.The effect of liver transplantation for primary sclerosing cholangitis on disease activity in patients with inflammatory bowel disease.Gastroenterol Hepatol(N Y)2013;9:434-441[PMID:23935552]
70 Mouchli MA,Singh S,Boardman L,Bruining DH,Lightner AL,Rosen CB,Heimbach JK,Hasan B,Poterucha JJ,Watt KD,Kane SV,Raffals LE,Loftus EV.Natural History of Established and De Novo Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis.Inflamm Bowel Dis 2018;24:1074-1081[PMID:29522202 DOI:10.1093/ibd/izx096]
71 Lindor KD,Wiesner RH,Colwell LJ,Steiner B,Beaver S,LaRusso NF.The combination of prednisone and colchicine in patients with primary sclerosing cholangitis.Am J Gastroenterol 1991;86:57-61[PMID:1986556]
72 van Hoogstraten HJ,Vleggaar FP,Boland GJ,van Steenbergen W,Griffioen P,Hop WC,van Hattum J,van Berge Henegouwen GP,Schalm SW,van Buuren HR.Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis:a randomized double-blind pilot study.BelgianDutch PSC Study Group.Am J Gastroenterol 2000;95:2015-2022[PMID:10950051 DOI:10.1111/j.1572-0241.2000.02267.x]
73 Angulo P,Batts KP,Jorgensen RA,LaRusso NA,Lindor KD.Oral budesonide in the treatment of primary sclerosing cholangitis.Am J Gastroenterol 2000;95:2333-2337[PMID:11007238 DOI:10.1111/j.1572-0241.2000.02323.x]
74 Knox TA,Kaplan MM.A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis.Gastroenterology 1994;106:494-499[PMID:8299916]
75 Lindor KD,Jorgensen RA,Anderson ML,Gores GJ,Hofmann AF,LaRusso NF.Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis:a pilot study.Am J Gastroenterol 1996;91:511-515[PMID:8633500]
76 Sterling RK,Salvatori JJ,Luketic VA,Sanyal AJ,Fulcher AS,Stravitz RT,Contos MJ,Mills AS,Shiffman ML.A prospective,randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis.Aliment Pharmacol Ther 2004;20:943-949[PMID:15521841 DOI:10.1111/j.1365-2036.2004.02214.x]
77 Talwalkar JA,Angulo P,Keach JC,Petz JL,Jorgensen RA,Lindor KD.Mycophenolate mofetil for the treatment of primary sclerosing cholangitis.Am J Gastroenterol 2005;100:308-312[PMID:15667487DOI:10.1111/j.1572-0241.2005.40484.x]
78 Van Thiel DH,Carroll P,Abu-Elmagd K,Rodriguez-Rilo H,Irish W,McMichael J,Starzl TE.Tacrolimus(FK 506),a treatment for primary sclerosing cholangitis:results of an open-label preliminary trial.Am J Gastroenterol 1995;90:455-459[PMID:7532912]
79 Hommes DW,Erkelens W,Ponsioen C,Stokkers P,Rauws E,van der Spek M,ten Kate F,van Deventer SJ.A double-blind,placebo-controlled,randomized study of infliximab in primary sclerosing cholangitis.J Clin Gastroenterol 2008;42:522-526[PMID:18344886 DOI:10.1097/MCG.0b013e3181662426]
80 Epstein MP,Kaplan MM.A pilot study of etanercept in the treatment of primary sclerosing cholangitis.Dig Dis Sci 2004;49:1-4[PMID:14992426]
81 Franceschet I,Cazzagon N,Del Ross T,D'IncàR,Buja A,Floreani A.Primary sclerosing cholangitis associated with inflammatory bowel disease:an observational study in a Southern Europe population focusing on new therapeutic options.Eur J Gastroenterol Hepatol 2016;28:508-513[PMID:26872110DOI:10.1097/MEG.0000000000000596]
82 Dubinsky MC,Cross RK,Sandborn WJ,Long M,Song X,Shi N,Ding Y,Eichner S,Pappalardo B,Ganguli A,Wang A.Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease.Inflamm Bowel Dis 2018[PMID:29668916 DOI:10.1093/ibd/izy065]
83 Gregorio GV,Portmann B,Karani J,Harrison P,Donaldson PT,Vergani D,Mieli-Vergani G.Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood:a 16-year prospective study.Hepatology 2001;33:544-553[PMID:11230733 DOI:10.1053/jhep.2001.22131]
84 Pallavicino F,Pellicano R,Reggiani S,Simondi D,Sguazzini C,Bonagura AG,CisaròF,Rizzetto M,Astegiano M.Inflammatory bowel diseases and primary sclerosing cholangitis:hepatic and pancreatic side effects due to azathioprine.Eur Rev Med Pharmacol Sci 2013;17:84-87[PMID:23329527]
85 Cardile S,Candusso M,Papadatou B,Bracci F,Knafelz D,Torre G.Lack of efficacy of infliximab in the treatment of primary sclerosing cholangitis in inflammatory bowel diseases in childhood.Eur JGastroenterol Hepatol 2017;29:736[PMID:28441268 DOI:10.1097/MEG.0000000000000847]
86 Ricciuto A,Fish J,Carman N,Walters TD,Church PC,Hansen BE,Crowley E,Siddiqui I,Nguyen GC,Kamath BM,Griffiths AM.Symptoms Do Not Correlate With Findings From Colonoscopy in Children With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.Clin Gastroenterol Hepatol 2018;16:1098-1105.e1[PMID:29378308 DOI:10.1016/j.cgh.2018.01.020]
87 BrooméU,L?fberg R,Lundqvist K,Veress B.Subclinical time span of inflammatory bowel disease in patients with primary sclerosing cholangitis.Dis Colon Rectum 1995;38:1301-1305[PMID:7497843]
88 Lazaridis KN,LaRusso NF.Primary Sclerosing Cholangitis.N Engl J Med 2016;375:2501-2502
89 Dlugosz A,Barakat AM,Bj?rkstr?m NK,?st?,Bergquist A.Diagnostic yield of endomicroscopy for dysplasia in primary sclerosing cholangitis associated inflammatory bowel disease:a feasibility study.Endosc Int Open 2016;4:E901-E911[PMID:27540581 DOI:10.1055/s-0042-111203]
90 Levy C.Evolving role of obeticholic acid in primary biliary cholangitis.Hepatology 2018;67:1666-1668[PMID:29222924 DOI:10.1002/hep.29726]
91 Miethke AG,Zhang W,Simmons J,Taylor AE,Shi T,Shanmukhappa SK,Karns R,White S,Jegga AG,Lages CS,Nkinin S,Keller BT,Setchell KD.Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice.Hepatology 2016;63:512-523[PMID:26172874 DOI:10.1002/hep.27973]
92 Assis DN,Abdelghany O,Cai SY,Gossard AA,Eaton JE,Keach JC,Deng Y,Setchell KD,Ciarleglio M,Lindor KD,Boyer JL.Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis:A Human Pilot Study.J Clin Gastroenterol 2017;51:e11-e16[PMID:27428727 DOI:10.1097/MCG.0000000000000591]
93 Friedman SL,Ratziu V,Harrison SA,Abdelmalek MF,Aithal GP,Caballeria J,Francque S,Farrell G,Kowdley KV,Craxi A,Simon K,Fischer L,Melchor-Khan L,Vest J,Wiens BL,Vig P,Seyedkazemi S,Goodman Z,Wong VW,Loomba R,Tacke F,Sanyal A,Lefebvre E.A randomized,placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.Hepatology 2018;67:1754-1767[PMID:28833331 DOI:10.1002/hep.29477]
94 Yu DC,Mennone A,Vig P,Boyer J.Cenicriviroc,a cytokine receptor antagonist,potentiated the effects of all-trans retinoic acid by reducing neutrophils and T cells in the liver of rodent cholestatic models.Hepatology 2017;66:938-939
95 Waye JD.Endoscopic retrograde cholangiopancreatography in the infant.Am J Gastroenterol 1976;65:461-463[PMID:949055]
96 Vegting IL,Tabbers MM,Taminiau JA,Aronson DC,Benninga MA,Rauws EA.Is endoscopic retrograde cholangiopancreatography valuable and safe in children of all ages?J Pediatr Gastroenterol Nutr 2009;48:66-71[PMID:19172126 DOI:10.1097/MPG.0b013e31817a24cf]
97 Rosen JD,Lane RS,Martinez JM,Perez EA,Tashiro J,Wagenaar AE,Van Haren RM,Kumar A,Sola JE.Success and safety of endoscopic retrograde cholangiopancreatography in children.J Pediatr Surg2017;52:1148-1151[PMID:28188033 DOI:10.1016/j.jpedsurg.2017.01.051]
98 Keane MG,Kumar M,Cieplik N,Thorburn D,Johnson GJ,Webster GJ,Chapman MH,Lindley KJ,Pereira SP.Paediatric pancreaticobiliary endoscopy:a 21-year experience from a tertiary hepatobiliary centre and systematic literature review.BMC Pediatr 2018;18:42[PMID:29426291 DOI:10.1186/s12887-017-0959-9]
99 Bonasso PC,Gurien LA,Staszak J,Gowen ME,Troendle DM,Odiase E,Lazar L,Ruan W,Barth BA,Williams RF,Dassinger MS.In-Hospital Pediatric ERCP is Associated with Shorter Hospitalization for Children with Choledocholithiasis.J Pediatr Gastroenterol Nutr 2018[PMID:30044307]
100 Troendle DM,Barth BA.ERCP can be safely and effectively performed by a pediatric gastroenterologist for choledocholithiasis in a pediatric facility.J Pediatr Gastroenterol Nutr 2013;57:655-658[PMID:24048163 DOI:10.1097/MPG.0000000000000124]
101 Lindor KD,Kowdley KV,Harrison ME;American College of Gastroenterology.ACG Clinical Guideline:Primary Sclerosing Cholangitis.Am J Gastroenterol 2015;110:646-59;quiz 660[PMID:25869391 DOI:10.1038/ajg.2015.112]
102 Stiehl A,Rudolph G,Kl?ters-Plachky P,Sauer P,Walker S.Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid:outcome after endoscopic treatment.J Hepatol 2002;36:151-156[PMID:11830325]
103 Kaya M,Petersen BT,Angulo P,Baron TH,Andrews JC,Gostout CJ,Lindor KD.Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis.Am J Gastroenterol 2001;96:1059-1066[PMID:11316147 DOI:10.1111/j.1572-0241.2001.03690.x]
104 Aabakken L,Karlsen TH,Albert J,Arvanitakis M,Chazouilleres O,Dumonceau JM,F?rkkil?M,Fickert P,Hirschfield GM,Laghi A,Marzioni M,Fernandez M,Pereira SP,Pohl J,Poley JW,Ponsioen CY,Schramm C,Swahn F,Tringali A,Hassan C.Role of endoscopy in primary sclerosing cholangitis:European Society of Gastrointestinal Endoscopy(ESGE)and European Association for the Study of the Liver(EASL)Clinical Guideline.Endoscopy 2017;49:588-608[PMID:28420030 DOI:10.1055/s-0043-107029]
105 Ponsioen CY,Arnelo U,Bergquist A,Rauws EA,Paulsen V,CantúP,Parzanese I,De Vries EM,van Munster KN,Said K,Chazouillères O,Desaint B,Kemgang A,F?rkkil?M,Van der Merwe S,Van Steenbergen W,Marschall HU,Stotzer PO,Thorburn D,Pereira SP,Aabakken L.No Superiority of Stents vs Balloon Dilatation for Dominant Strictures in Patients With Primary Sclerosing Cholangitis.Gastroenterology 2018;155:752-759.e5[PMID:29803836 DOI:10.1053/j.gastro.2018.05.034]
106 Liu R,Cox K,Guthery SL,Book L,Witt B,Chadwick B,Adler DG.Cholangiocarcinoma and high-grade dysplasia in young patients with primary sclerosing cholangitis.Dig Dis Sci 2014;59:2320-2324[PMID:24748183 DOI:10.1007/s10620-014-3152-0]
107 Njei B,McCarty TR,Varadarajulu S,Navaneethan U.Systematic review with meta-analysis:endoscopic retrograde cholangiopancreatography-based modalities for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis.Aliment Pharmacol Ther 2016;44:1139-1151[PMID:27696456 DOI:10.1111/apt.13817]
108 Barkin JA,Levy C,Souto EO.Endoscopic Management of Primary Sclerosing Cholangitis.Ann Hepatol2017;16:842-850[PMID:29055922 DOI:10.5604/01.3001.0010.5274]
109 Imani Fooladi AA,Mahmoodzadeh Hosseini H,Nourani MR,Khani S,Alavian SM.Probiotic as a novel treatment strategy against liver disease.Hepat Mon 2013;13:e7521[PMID:23610585 DOI:10.5812/hepatmon.7521]
110 Jones EA,Molenaar HA,Oosting J.Ondansetron and pruritus in chronic liver disease:a controlled study.Hepatogastroenterology 2007;54:1196-1199[PMID:17629069]
111 Neff GW,O'Brien CB,Reddy KR,Bergasa NV,Regev A,Molina E,Amaro R,Rodriguez MJ,Chase V,Jeffers L,Schiff E.Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease.Am J Gastroenterol 2002;97:2117-2119[PMID:12190187 DOI:10.1111/j.1572-0241.2002.05852.x]
112 Bolier AR,Peri S,Oude Elferink RP,Beuers U.The challenge of cholestatic pruritus.Acta Gastroenterol Belg 2012;75:399-404[PMID:23402082]
113 Reig A,SeséP,Parés A.Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.Am J Gastroenterol 2018;113:49-55[PMID:29016567 DOI:10.1038/ajg.2017.287]
114 Corpechot C,Chazouilleres O,Rousseau A.A 2-year multicenter,double-blind,randomized,placebocontrolled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate response to ursodeoxycholic acid therapy.Hepatology 2017;66
115 Ponsioen CY,Chapman RW,Chazouillères O,Hirschfield GM,Karlsen TH,Lohse AW,Pinzani M,Schrumpf E,Trauner M,Gores GJ.Surrogate endpoints for clinical trials in primary sclerosing cholangitis:Review and results from an International PSC Study Group consensus process.Hepatology 2016;63:1357-1367[PMID:26418478 DOI:10.1002/hep.28256]
116 Laboratories MM.Alkaline Phosphatase,Total and Isozymes,Serum:Clinical and Interpretive.Hepatology 2017;64:256-258
117 Turan S,Topcu B,G?k?e?,Güran T,Atay Z,Omar A,Ak?ay T,Bereket A.Serum alkaline phosphatase levels in healthy children and evaluation of alkaline phosphatase z-scores in different types of rickets.J Clin Res Pediatr Endocrinol 2011;3:7-11[PMID:21448327 DOI:10.4274/jcrpe.v3i1.02]
118 Otero JL,González-Peralta RP,Andres JM,Jolley CD,Novak DA,Haafiz A.Elevated Alkaline Phosphatase in Children:An Algorithm to Determine When a"Wait and See"Approach is Optimal.Clin Med Insights Pediatr 2011;5:15-18[PMID:23761996 DOI:10.4137/CMPed.S6872]
119 Vesterhus M,Hov JR,Holm A,Schrumpf E,Nyg?rd S,Godang K,Andersen IM,Naess S,Thorburn D,Saffioti F,Vatn M,Gilja OH,Lund-Johansen F,Syversveen T,Brabrand K,Parés A,Ponsioen CY,Pinzani M,F?rkkil?M,Moum B,Ueland T,R?sj?H,Rosenberg W,Boberg KM,Karlsen TH.Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis.Hepatology 2015;62:188-197[PMID:25833813 DOI:10.1002/hep.27825]
120 Serai SD,Trout AT,Miethke A,Diaz E,Xanthakos SA,Dillman JR.Putting it all together:established and emerging MRI techniques for detecting and measuring liver fibrosis.Pediatr Radiol 2018;48:1256-1272[PMID:30078038 DOI:10.1007/s00247-018-4083-2]
121 Goldberg D,French B,Thomasson A,Reddy KR,Halpern SD.Waitlist survival of patients with primary sclerosing cholangitis in the model for end-stage liver disease era.Liver Transpl 2011;17:1355-1363[PMID:21837735 DOI:10.1002/lt.22396]
122 Jossen J,Annunziato R,Kim HS,Chu J,Arnon R.Liver Transplantation for Children With Primary Sclerosing Cholangitis and Autoimmune Hepatitis:UNOS Database Analysis.J Pediatr Gastroenterol Nutr 2017;64:e83-e87[PMID:27755342 DOI:10.1097/MPG.0000000000001438]
123 Miloh T,Anand R,Yin W,Vos M,Kerkar N,Alonso E;Studies of Pediatric Liver Transplantation Research Group.Pediatric liver transplantation for primary sclerosing cholangitis.Liver Transpl 2011;17:925-933[PMID:21506253 DOI:10.1002/lt.22320]
124 Goldberg DS,French B,Thomasson A,Reddy KR,Halpern SD.Current trends in living donor liver transplantation for primary sclerosing cholangitis.Transplantation 2011;91:1148-1152[PMID:21544035DOI:10.1097/TP.0b013e31821694b3]
125 Deneau MR,Amin M,Amir AZ,Auth M,Bazerbachi F,Broderick A,El-Youssef M,Ferrari F,Furuya KN,Gottrand F,Gupta N,Homan M,Kamath BM,Lin H,Mo Kim K,Kolho KL,Konidari A,Koot B,Iorio R,Jensen MK,Mack C,Martinez M,Ricciuto A,Smolka V,Tanaka A,Valentino PL,Venkat V,Vitola B,Vos MB,Woynarowski M,Yap J,Miloh T.MELD score and liver transplantation in children with primary sclerosing cholangitis.Pediatric Gastroenterology Nutrition 2018;67
126 Hoffmann K,Hinz U,Hillebrand N,Ganten T,Gotthardt D,Longerich T,Schirmacher P,Schemmer P.The MELD score predicts the short-term and overall survival after liver transplantation in patients with primary sclerosing cholangitis or autoimmune liver diseases.Langenbecks Arch Surg 2014;399:1001-1009[PMID:25106131 DOI:10.1007/s00423-014-1237-z]
127 Darwish Murad S,Kim WR,Harnois DM,Douglas DD,Burton J,Kulik LM,Botha JF,Mezrich JD,Chapman WC,Schwartz JJ,Hong JC,Emond JC,Jeon H,Rosen CB,Gores GJ,Heimbach JK.Efficacy of neoadjuvant chemoradiation,followed by liver transplantation,for perihilar cholangiocarcinoma at 12 UScenters.Gastroenterology 2012;143:88-98.e3;quiz e14[PMID:22504095 DOI:10.1053/j.gastro.2012.04.008]
128 J?rgensen KK,Lindstr?m L,Cvancarova M,Karlsen TH,Castedal M,Friman S,Schrumpf E,Foss A,Isoniemi H,Nordin A,Holte K,Rasmussen A,Bergquist A,Vatn MH,Boberg KM.Immunosuppression after liver transplantation for primary sclerosing cholangitis influences activity of inflammatory bowel disease.Clin Gastroenterol Hepatol 2013;11:517-523[PMID:23333218 DOI:10.1016/j.cgh.2012.12.027]
129 Verdonk RC,Dijkstra G,Haagsma EB,Shostrom VK,Van den Berg AP,Kleibeuker JH,Langnas AN,Sudan DL.Inflammatory bowel disease after liver transplantation:risk factors for recurrence and de novo disease.Am J Transplant 2006;6:1422-1429[PMID:16686766 DOI:10.1111/j.1600-6143.2006.01333.x]
130 Buchholz BM,Lykoudis PM,Ravikumar R,Pollok JM,Fusai GK.Role of colectomy in preventing recurrent primary sclerosing cholangitis in liver transplant recipients.World J Gastroenterol 2018;24:3171-3180[PMID:30065563 DOI:10.3748/wjg.v24.i28.3171]
131 Goldberg DS,French B,Abt PL,Olthoff K,Shaked A.Superior survival using living donors and donorrecipient matching using a novel living donor risk index.Hepatology 2014;60:1717-1726[PMID:25042283 DOI:10.1002/hep.27307]
132 Wells MM,Croome KP,Boyce E,Chandok N.Roux-en-Y choledochojejunostomy versus duct-to-duct biliary anastomosis in liver transplantation for primary sclerosing cholangitis:a meta-analysis.Transplant Proc 2013;45:2263-2271[PMID:23953538 DOI:10.1016/j.transproceed.2013.01.066]
133 Bezinover D,Iskandarani K,Chinchilli V,McQuillan P,Saner F,Kadry Z,Riley TR,Janicki PK.Autoimmune conditions are associated with perioperative thrombotic complications in liver transplant recipients:A UNOS database analysis.BMC Anesthesiol 2016;16:26[PMID:27207434 DOI:10.1186/s12871-016-0192-3]
134 Montano-Loza AJ,Bhanji RA,Wasilenko S,Mason AL.Systematic review:recurrent autoimmune liver diseases after liver transplantation.Aliment Pharmacol Ther 2017;45:485-500[PMID:27957759 DOI:10.1111/apt.13894]
135 Deneau MR,El-Matary W,Valentino PL,Abdou R,Alqoaer K,Amin M,Amir AZ,Auth M,Bazerbachi F,Broderick A,Chan A,Cotter J,Doan S,El-Youssef M,Ferrari F,Furuya KN,Gottrand M,Gottrand F,Gupta N,Homan M,Kamath BM,Mo Kim K,Kolho KL,Konidari A,Koot B,Iorio R,Ledder O,Mack C,Martinez M,Miloh T,Mohan P,O'Cathain N,Papadopoulou A,Ricciuto A,Saubermann L,Sathya P,Shteyer E,Smolka V,Tanaka A,Varier R,Venkat V,Vitola B,Vos MB,Woynarowski M,Yap J,Jensen MK.Recurrence of primary sclerosing cholangitis after liver transplantation in children:data from the Pediatric PSC Consortium.Hepatology 2017;66:S76
136 Soufi N,Bazerbachi F,Deneau M.Post-Transplant Disease Recurrence in Pediatric PSC.Curr Gastroenterol Rep 2018;20:44[PMID:30083892 DOI:10.1007/s11894-018-0649-2]
137 Yamada Y,Hoshino K,Fuchimoto Y,Matsubara K,Hibi T,Yagi H,Abe Y,Shinoda M,Kitago M,Obara H,Yagi T,Okajima H,Kaido T,Uemoto S,Suzuki T,Kubota K,Yoshizumi T,Maehara Y,Inomata Y,Kitagawa Y,Egawa H,Kuroda T.Rituximab Induction to Prevent the Recurrence of PSC After Liver Transplantation-The Lessons Learned From ABO-Incompatible Living Donor Liver Transplantation.Transplant Direct 2018;4:e342[PMID:29464203 DOI:10.1097/TXD.0000000000000760]
138 Singh S,Edakkanambeth Varayil J,Loftus EV,Talwalkar JA.Incidence of colorectal cancer after liver transplantation for primary sclerosing cholangitis:a systematic review and meta-analysis.Liver Transpl2013;19:1361-1369[PMID:24019127 DOI:10.1002/lt.23741]
139 Altwegg R,Combes R,Laharie D,De Ledinghen V,Radenne S,Conti F,Chazouilleres O,Duvoux C,Dumortier J,Leroy V,Treton X,Durand F,Dharancy S,Nachury M,Goutorbe F,Lamblin G,Boivineau L,Peyrin-Biroulet L,Pageaux GP.Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis:A nationwide case series.Dig Liver Dis 2018;50:668-674[PMID:29655972 DOI:10.1016/j.dld.2018.02.014]
2 Deneau MR,El-Matary W,Valentino PL,Abdou R,Alqoaer K,Amin M,Amir AZ,Auth M,Bazerbachi F,Broderick A,Chan A,Cotter J,Doan S,El-Youssef M,Ferrari F,Furuya KN,Gottrand M,Gottrand F,Gupta N,Homan M,Kamath BM,Kim KM,Kolho KL,Konidari A,Koot B,Iorio R,Ledder O,Mack C,Martinez M,Miloh T,Mohan P,O'Cathain N,Papadopoulou A,Ricciuto A,Saubermann L,Sathya P,Shteyer E,Smolka V,Tanaka A,Varier R,Venkat V,Vitola B,Vos MB,Woynarowski M,Yap J,Jensen MK.The natural history of primary sclerosing cholangitis in 781 children:A multicenter,international collaboration.Hepatology 2017;66:518-527[PMID:28390159 DOI:10.1002/hep.29204]
3 Dyson JK,Webb G,Hirschfield GM,Lohse A,Beuers U,Lindor K,Jones DE.Unmet clinical need in autoimmune liver diseases.J Hepatol 2015;62:208-218[PMID:25234946 DOI:10.1016/j.jhep.2014.09.010]
4 Damman JL,Rodriguez EA,Ali AH,Buness CW,Cox KL,Carey EJ,Lindor KD.Review article:the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis.Aliment Pharmacol Ther 2018;47:886-895[PMID:29411404 DOI:10.1111/apt.14540]
5 Smit JJ,Schinkel AH,Oude Elferink RP,Groen AK,Wagenaar E,van Deemter L,Mol CA,Ottenhoff R,van der Lugt NM,van Roon MA.Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease.Cell 1993;75:451-462[PMID:8106172]
6 Hohenester S,Wenniger LM,Paulusma CC,van Vliet SJ,Jefferson DM,Elferink RP,Beuers U.A biliary HCO3-umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes.Hepatology 2012;55:173-183[PMID:21932391 DOI:10.1002/hep.24691]
7 Fickert P,Hirschfield GM,Denk G,Marschall HU,Altorjay I,F?rkkil?M,Schramm C,Spengler U,Chapman R,Bergquist A,Schrumpf E,Nevens F,Trivedi P,Reiter FP,Tornai I,Halilbasic E,Greinwald R,Pr?ls M,Manns MP,Trauner M;European PSC norUDCA Study Group.norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.J Hepatol 2017;67:549-558[PMID:28529147DOI:10.1016/j.jhep.2017.05.009]
8 Fernandez-Barrena MG,Barcena-Varela M,Banales JM.New evidence supporting the biliary bicarbonate umbrella theory.Clin Res Hepatol Gastroenterol 2017;41:126-128[PMID:27818187 DOI:10.1016/j.clinre.2016.09.004]
9 Galle PR,Theilmann L,Raedsch R,Otto G,Stiehl A.Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes.Hepatology 1990;12:486-491[PMID:2401454]
10 Stiehl A,Rudolph G,Raedsch R,M?ller B,Hopf U,Lotterer E,Bircher J,F?lsch U,Klaus J,Endele R.Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis.Hepatology 1990;12:492-497[PMID:2401455]
11 Calmus Y,Gane P,Rouger P,Poupon R.Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis:effect of ursodeoxycholic acid.Hepatology 1990;11:12-15[PMID:2403961]
12 Lindor KD,Dickson ER,Baldus WP,Jorgensen RA,Ludwig J,Murtaugh PA,Harrison JM,Wiesner RH,Anderson ML,Lange SM.Ursodeoxycholic acid in the treatment of primary biliary cirrhosis.Gastroenterology 1994;106:1284-1290[PMID:8174890]
13 Lindor KD,Therneau TM,Jorgensen RA,Malinchoc M,Dickson ER.Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis.Gastroenterology 1996;110:1515-1518[PMID:8613058]
14 Lindor KD.Ursodiol for primary sclerosing cholangitis.Mayo Primary Sclerosing CholangitisUrsodeoxycholic Acid Study Group.N Engl J Med 1997;336:691-695[PMID:9041099 DOI:10.1056/NEJM199703063361003]
15 Cullen SN,Rust C,Fleming K,Edwards C,Beuers U,Chapman RW.High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective.J Hepatol 2008;48:792-800[PMID:18314215 DOI:10.1016/j.jhep.2007.12.023]
16 Olsson R,Boberg KM,de Muckadell OS,Lindgren S,Hultcrantz R,Folvik G,Bell H,Gangs?yKristiansen M,Matre J,Rydning A,Wikman O,Danielsson A,Sandberg-Gertzén H,Ung KA,Eriksson A,L??f L,Prytz H,Marschall HU,BrooméU.High-dose ursodeoxycholic acid in primary sclerosing cholangitis:a 5-year multicenter,randomized,controlled study.Gastroenterology 2005;129:1464-1472[PMID:16285948 DOI:10.1053/j.gastro.2005.08.017]
17 Harnois DM,Angulo P,Jorgensen RA,Larusso NF,Lindor KD.High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis.Am J Gastroenterol 2001;96:1558-1562[PMID:11374699 DOI:10.1111/j.1572-0241.2001.03777.x]
18 Lindor KD,Kowdley KV,Luketic VA,Harrison ME,McCashland T,Befeler AS,Harnois D,Jorgensen R,Petz J,Keach J,Mooney J,Sargeant C,Braaten J,Bernard T,King D,Miceli E,Schmoll J,Hoskin T,Thapa P,Enders F.High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.Hepatology 2009;50:808-814[PMID:19585548 DOI:10.1002/hep.23082]
19 Chapman MH,Webster GJ,Bannoo S,Johnson GJ,Wittmann J,Pereira SP.Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis:a 25-year single-centre experience.Eur J Gastroenterol Hepatol 2012;24:1051-1058[PMID:22653260 DOI:10.1097/MEG.0b013e3283554bbf]
20 Chapman R,Fevery J,Kalloo A,Nagorney DM,Boberg KM,Shneider B,Gores GJ;American Association for the Study of Liver Diseases.Diagnosis and management of primary sclerosing cholangitis.Hepatology 2010;51:660-678[PMID:20101749 DOI:10.1002/hep.23294]
21 Ponsioen CY,Lindor KD,Mehta R,Dimick-Santos L.Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis.Hepatology 2018;68:1174-1188[PMID:29574971 DOI:10.1002/hep.29882]
22 Wunsch E,Trottier J,Milkiewicz M,Raszeja-Wyszomirska J,Hirschfield GM,Barbier O,Milkiewicz P.Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis.Hepatology 2014;60:931-940[PMID:24519384 DOI:10.1002/hep.27074]
23 Tabibian JH,Lindor KD.Ursodeoxycholic acid in primary sclerosing cholangitis:if withdrawal is bad,then administration is good(right?).Hepatology 2014;60:785-788[PMID:24752961 DOI:10.1002/hep.27180]
24 Deneau MR,Mack C,Abdou R,Amin M,Amir A,Auth M,Bazerbachi F,Marie Broderick A,Chan A,DiGuglielmo M,El-Matary W,El-Youssef M,Ferrari F,Furuya KN,Gottrand F,Gupta N,Homan M,Jensen MK,Kamath BM,Mo Kim K,Kolho KL,Konidari A,Koot B,Iorio R,Martinez M,Mohan P,Palle S,Papadopoulou A,Ricciuto A,Saubermann L,Sathya P,Shteyer E,Smolka V,Tanaka A,Valentino PL,Varier R,Venkat V,Vitola B,Vos MB,Woynarowski M,Yap J,Miloh T.Gamma Glutamyltransferase Reduction Is Associated With Favorable Outcomes in Pediatric Primary Sclerosing Cholangitis.Hepatol Commun 2018;2:1369-1378[PMID:30411083 DOI:10.1002/hep4.1251]
25 Lindstr?m L,Hultcrantz R,Boberg KM,Friis-Liby I,Bergquist A.Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis.Clin Gastroenterol Hepatol 2013;11:841-846[PMID:23353641 DOI:10.1016/j.cgh.2012.12.032]
26 Al Mamari S,Djordjevic J,Halliday JS,Chapman RW.Improvement of serum alkaline phosphatase to<1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis.J Hepatol 2013;58:329-334[PMID:23085647 DOI:10.1016/j.jhep.2012.10.013]
27 Rupp C,R?ssler A,Halibasic E,Sauer P,Weiss KH,Friedrich K,Wannhoff A,Stiehl A,Stremmel W,Trauner M,Gotthardt DN.Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis,independent of dominant stenosis.Aliment Pharmacol Ther 2014;40:1292-1301[PMID:25316001 DOI:10.1111/apt.12979]
28 de Vries EM,Wang J,Leeflang MM,Boonstra K,Weersma RK,Beuers UH,Geskus RB,Ponsioen CY.Alkaline phosphatase at diagnosis of primary sclerosing cholangitis and 1 year later:evaluation of prognostic value.Liver Int 2016;36:1867-1875[PMID:26945698 DOI:10.1111/liv.13110]
29 Stanich PP,Bj?rnsson E,Gossard AA,Enders F,Jorgensen R,Lindor KD.Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis.Dig Liver Dis 2011;43:309-313[PMID:21251891 DOI:10.1016/j.dld.2010.12.008]
30 Imam MH,Sinakos E,Gossard AA,Kowdley KV,Luketic VA,Edwyn Harrison M,McCashland T,Befeler AS,Harnois D,Jorgensen R,Petz J,Keach J,DeCook AC,Enders F,Lindor KD.High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis.Aliment Pharmacol Ther 2011;34:1185-1192[PMID:21957881 DOI:10.1111/j.1365-2036.2011.04863.x]
31 Gilger MA,Gann ME,Opekun AR,Gleason WA.Efficacy of ursodeoxycholic acid in the treatment of primary sclerosing cholangitis in children.J Pediatr Gastroenterol Nutr 2000;31:136-141[PMID:10941964]
32 Black D MC,Kerkar N,Miloh T,Sundaram S,Anand R,Gupta A,Alonso E,Arnon R,Bulut P,Karpen S,Lin C,Rosenthal P,Ryan M,Squires R,Valentino P,Schneider B.Initial Results of the WUPPSCStudy-Prospective Multicenter Withdrawal of Ursodeoxycholic Acid in Pediatric Primary Sclerosing Cholangitis.Gastroenterology 2018;154:S1209
33 Lichtman SN,Sartor RB,Keku J,Schwab JH.Hepatic inflammation in rats with experimental small intestinal bacterial overgrowth.Gastroenterology 1990;98:414-423[PMID:2295397]
34 Rossen NG,Fuentes S,Boonstra K,D'Haens GR,Heilig HG,Zoetendal EG,de Vos WM,Ponsioen CY.The mucosa-associated microbiota of PSC patients is characterized by low diversity and low abundance of uncultured Clostridiales II.J Crohns Colitis 2015;9:342-348[PMID:25547975 DOI:10.1093/ecco-jcc/jju023]
35 Grant AJ,Lalor PF,Hübscher SG,Briskin M,Adams DH.MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium(MAdCAM-1 in chronic inflammatory liver disease).Hepatology 2001;33:1065-1072[PMID:11343233 DOI:10.1053/jhep.2001.24231]
36 Kevans D,Tyler AD,Holm K,J?rgensen KK,Vatn MH,Karlsen TH,Kaplan GG,Eksteen B,Gevers D,Hov JR,Silverberg MS.Characterization of Intestinal Microbiota in Ulcerative Colitis Patients with and without Primary Sclerosing Cholangitis.J Crohns Colitis 2016;10:330-337[PMID:26526357 DOI:10.1093/ecco-jcc/jjv204]
37 Kummen M,Holm K,Anmarkrud JA,Nyg?rd S,Vesterhus M,H?ivik ML,Tr?seid M,Marschall HU,Schrumpf E,Moum B,R?sj?H,Aukrust P,Karlsen TH,Hov JR.The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls.Gut 2017;66:611-619[PMID:26887816 DOI:10.1136/gutjnl-2015-310500]
38 Sabino J,Vieira-Silva S,Machiels K,Joossens M,Falony G,Ballet V,Ferrante M,Van Assche G,Van der Merwe S,Vermeire S,Raes J.Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD.Gut 2016;65:1681-1689[PMID:27207975 DOI:10.1136/gutjnl-2015-311004]
39 Iwasawa K,Suda W,Tsunoda T,Oikawa-Kawamoto M,Umetsu S,Takayasu L,Inui A,Fujisawa T,Morita H,Sogo T,Hattori M.Dysbiosis of the salivary microbiota in pediatric-onset primary sclerosing cholangitis and its potential as a biomarker.Sci Rep 2018;8:5480[PMID:29615776 DOI:10.1038/s41598-018-23870-w]
40 Tabibian JH,Gossard A,El-Youssef M,Eaton JE,Petz J,Jorgensen R,Enders FB,Tabibian A,Lindor KD.Prospective Clinical Trial of Rifaximin Therapy for Patients With Primary Sclerosing Cholangitis.Am J Ther 2017;24:e56-e63[PMID:24914504 DOI:10.1097/MJT.0000000000000102]
41 Mistilis SP,Skyring AP,Goulston SJ.Effect of long-term tetracycline therapy,steroid therapy and colectomy in pericholangitis associated with ulcerative colitis.Australas Ann Med 1965;14:286-294[PMID:5861251]
42 Silveira MG,Torok NJ,Gossard AA,Keach JC,Jorgensen RA,Petz JL,Lindor KD.Minocycline in the treatment of patients with primary sclerosing cholangitis:results of a pilot study.Am J Gastroenterol 2009;104:83-88[PMID:19098854 DOI:10.1038/ajg.2008.14]
43 F?rkkil?M,Karvonen AL,Nurmi H,Nuutinen H,Taavitsainen M,Pikkarainen P,K?rkk?inen P.Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis:a randomized placebocontrolled trial.Hepatology 2004;40:1379-1386[PMID:15565569 DOI:10.1002/hep.20457]
44 Tabibian JH,Weeding E,Jorgensen RA,Petz JL,Keach JC,Talwalkar JA,Lindor KD.Randomised clinical trial:vancomycin or metronidazole in patients with primary sclerosing cholangitis-a pilot study.Aliment Pharmacol Ther 2013;37:604-612[PMID:23384404 DOI:10.1111/apt.12232]
45 Davies YK,Cox KM,Abdullah BA,Safta A,Terry AB,Cox KL.Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin:an immunomodulating antibiotic.J Pediatr Gastroenterol Nutr 2008;47:61-67[PMID:18607270 DOI:10.1097/MPG.0b013e31816fee95]
46 Moellering RC.Vancomycin:a 50-year reassessment.Clin Infect Dis 2006;42 Suppl 1:S3-S4[PMID:16323117 DOI:10.1086/491708]
47 Abarbanel DN,Seki SM,Davies Y,Marlen N,Benavides JA,Cox K,Nadeau KC,Cox KL.Immunomodulatory effect of vancomycin on Treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis.J Clin Immunol 2013;33:397-406[PMID:23054338 DOI:10.1007/s10875-012-9801-1]
48 Deneau MR,Amin M,Amir AZ,Auth M,Bazerbachi F,Broderick A,El-Youssef M,Ferrari F,Furuya KN,Gottrand F,Gupta N,Homan M,Kamath BM,Lin H,Mo Kim K,Kolho KL,Konidari A,Koot B,Iorio R,Jensen MK,Mack C,Martinez M,Ricciuto A,Smolka V,Tanaka A,Valentino PL,Venkat V,Vitola B,Vos MB,Woynarowski M,Yap J,Miloh T.Variability in Diagnostic and Therapeutic Strategies for Pediatric Primary Sclerosing Cholangitis between Centers in the Pediatric PSC Consortium.Hepatology 2018;68
49 Rahimpour S,Nasiri-Toosi M,Khalili H,Ebrahimi-Daryani N,Nouri-Taromlou MK,Azizi Z.A Triple Blinded,Randomized,Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis:a Pilot Study.J Gastrointestin Liver Dis 2016;25:457-464[PMID:27981301 DOI:10.15403/jgld.2014.1121.254.rah]
50 Valentino PL,Wiggins S,Harney S,Raza R,Lee CK,Jonas MM.The Natural History of Primary Sclerosing Cholangitis in Children:A Large Single-Center Longitudinal Cohort Study.J Pediatr Gastroenterol Nutr 2016;63:603-609[PMID:27504812 DOI:10.1097/MPG.0000000000001368]
51 Karlsen TH,Folseraas T,Thorburn D,Vesterhus M.Primary sclerosing cholangitis-a comprehensive review.J Hepatol 2017;67:1298-1323[PMID:28802875 DOI:10.1016/j.jhep.2017.07.022]
52 Ji SG,Juran BD,Mucha S,Folseraas T,Jostins L,Melum E,Kumasaka N,Atkinson EJ,Schlicht EM,Liu JZ,Shah T,Gutierrez-Achury J,Boberg KM,Bergquist A,Vermeire S,Eksteen B,Durie PR,Farkkila M,Müller T,Schramm C,Sterneck M,Weismüller TJ,Gotthardt DN,Ellinghaus D,Braun F,Teufel A,Laudes M,Lieb W,Jacobs G,Beuers U,Weersma RK,Wijmenga C,Marschall HU,Milkiewicz P,Pares A,Kontula K,Chazouillères O,Invernizzi P,Goode E,Spiess K,Moore C,Sambrook J,Ouwehand WH,Roberts DJ,Danesh J,Floreani A,Gulamhusein AF,Eaton JE,Schreiber S,Coltescu C,Bowlus CL,Luketic VA,Odin JA,Chopra KB,Kowdley KV,Chalasani N,Manns MP,Srivastava B,Mells G,Sandford RN,Alexander G,Gaffney DJ,Chapman RW,Hirschfield GM,de Andrade M;UK-PSCConsortium;International IBD Genetics Consortium;International PSC Study Group,Rushbrook SM,Franke A,Karlsen TH,Lazaridis KN,Anderson CA.Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease.Nat Genet 2017;49:269-273[PMID:27992413 DOI:10.1038/ng.3745]
53 Liu JZ,Hov JR,Folseraas T,Ellinghaus E,Rushbrook SM,Doncheva NT,Andreassen OA,Weersma RK,Weismüller TJ,Eksteen B,Invernizzi P,Hirschfield GM,Gotthardt DN,Pares A,Ellinghaus D,Shah T,Juran BD,Milkiewicz P,Rust C,Schramm C,Müller T,Srivastava B,Dalekos G,N?then MM,Herms S,Winkelmann J,Mitrovic M,Braun F,Ponsioen CY,Croucher PJ,Sterneck M,Teufel A,Mason AL,Saarela J,Leppa V,Dorfman R,Alvaro D,Floreani A,Onengut-Gumuscu S,Rich SS,Thompson WK,Schork AJ,N?ss S,Thomsen I,Mayr G,K?nig IR,Hveem K,Cleynen I,Gutierrez-Achury J,Rica?oPonce I,van Heel D,Bj?rnsson E,Sandford RN,Durie PR,Melum E,Vatn MH,Silverberg MS,Duerr RH,Padyukov L,Brand S,Sans M,Annese V,Achkar JP,Boberg KM,Marschall HU,Chazouillères O,Bowlus CL,Wijmenga C,Schrumpf E,Vermeire S,Albrecht M;UK-PSCSC Consortium,Rioux JD,Alexander G,Bergquist A,Cho J,Schreiber S,Manns MP,F?rkkil?M,Dale AM,Chapman RW,Lazaridis KN;International PSC Study Group,Franke A,Anderson CA,Karlsen TH;International IBDGenetics Consortium.Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis.Nat Genet 2013;45:670-675[PMID:23603763 DOI:10.1038/ng.2616]
54 Folseraas T,Melum E,Rausch P,Juran BD,Ellinghaus E,Shiryaev A,Laerdahl JK,Ellinghaus D,Schramm C,Weismüller TJ,Gotthardt DN,Hov JR,Clausen OP,Weersma RK,Janse M,Boberg KM,Bj?rnsson E,Marschall HU,Cleynen I,Rosenstiel P,Holm K,Teufel A,Rust C,Gieger C,Wichmann HE,Bergquist A,Ryu E,Ponsioen CY,Runz H,Sterneck M,Vermeire S,Beuers U,Wijmenga C,Schrumpf E,Manns MP,Lazaridis KN,Schreiber S,Baines JF,Franke A,Karlsen TH.Extended analysis of a genomewide association study in primary sclerosing cholangitis detects multiple novel risk loci.J Hepatol 2012;57:366-375[PMID:22521342 DOI:10.1016/j.jhep.2012.03.031]
55 Tse CS,Loftus EV,Raffals LE,Gossard AA,Lightner AL.Effects of vedolizumab,adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease.Aliment Pharmacol Ther 2018;48:190-195[PMID:29808485 DOI:10.1111/apt.14829]
56 Bj?rnsson E,Cederborg A,Akvist A,Simren M,Stotzer PO,Bjarnason I.Intestinal permeability and bacterial growth of the small bowel in patients with primary sclerosing cholangitis.Scand J Gastroenterol2005;40:1090-1094[PMID:16211716]
57 Tornai T,Palyu E,Vitalis Z,Tornai I,Tornai D,Antal-Szalmas P,Norman GL,Shums Z,Veres G,Dezsofi A,Par G,Par A,Orosz P,Szalay F,Lakatos PL,Papp M.Gut barrier failure biomarkers are associated with poor disease outcome in patients with primary sclerosing cholangitis.World JGastroenterol 2017;23:5412-5421[PMID:28839442 DOI:10.3748/wjg.v23.i29.5412]
58 Lichtman SN,Keku J,Schwab JH,Sartor RB.Hepatic injury associated with small bowel bacterial overgrowth in rats is prevented by metronidazole and tetracycline.Gastroenterology 1991;100:513-519[PMID:1985047]
59 Grant AJ,Lalor PF,Salmi M,Jalkanen S,Adams DH.Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease.Lancet 2002;359:150-157[PMID:11809275 DOI:10.1016/S0140-6736(02)07374-9]
60 Zweers SJ,Shiryaev A,Komuta M,Vesterhus M,Hov JR,Perugorria MJ,de Waart DR,Chang JC,Tol S,Te Velde AA,de Jonge WJ,Banales JM,Roskams T,Beuers U,Karlsen TH,Jansen PL,Schaap FG.Elevated interleukin-8 in bile of patients with primary sclerosing cholangitis.Liver Int 2016;36:1370-1377[PMID:26866350 DOI:10.1111/liv.13092]
61 Liu R,Zhao R,Zhou X,Liang X,Campbell DJ,Zhang X,Zhang L,Shi R,Wang G,Pandak WM,Sirica AE,Hylemon PB,Zhou H.Conjugated bile acids promote cholangiocarcinoma cell invasive growth through activation of sphingosine 1-phosphate receptor 2.Hepatology 2014;60:908-918[PMID:24700501 DOI:10.1002/hep.27085]
62 Sokol H,Cosnes J,Chazouilleres O,Beaugerie L,Tiret E,Poupon R,Seksik P.Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis.World JGastroenterol 2008;14:3497-3503[PMID:18567077]
63 Mendes FD,Levy C,Enders FB,Loftus EV,Angulo P,Lindor KD.Abnormal hepatic biochemistries in patients with inflammatory bowel disease.Am J Gastroenterol 2007;102:344-350[PMID:17100965DOI:10.1111/j.1572-0241.2006.00947.x]
64 Shiau H,Ihekweazu FD,Amin M,Fofanova T,Miloh T,Kellermayer R.Unique Inflammatory Bowel Disease Phenotype of Pediatric Primary Sclerosing Cholangitis:A Single-Center Study.J Pediatr Gastroenterol Nutr 2017;65:404-409[PMID:28141677 DOI:10.1097/MPG.0000000000001531]
65 Stockbrügger RW,Olsson R,Jaup B,Jensen J.Forty-six patients with primary sclerosing cholangitis:radiological bile duct changes in relationship to clinical course and concomitant inflammatory bowel disease.Hepatogastroenterology 1988;35:289-294[PMID:3215625]
66 Nordenvall C,Olén O,Nilsson PJ,von Seth E,Ekbom A,Bottai M,Myrelid P,Bergquist A.Colectomy prior to diagnosis of primary sclerosing cholangitis is associated with improved prognosis in a nationwide cohort study of 2594 PSC-IBD patients.Aliment Pharmacol Ther 2018;47:238-245[PMID:29064110DOI:10.1111/apt.14393]
67 Gulamhusein AF,Eaton JE,Tabibian JH,Atkinson EJ,Juran BD,Lazaridis KN.Duration of Inflammatory Bowel Disease Is Associated With Increased Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis and IBD.Am J Gastroenterol 2016;111:705-711[PMID:27002801 DOI:10.1038/ajg.2016.55]
68 de Vries AB,Janse M,Blokzijl H,Weersma RK.Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis.World J Gastroenterol 2015;21:1956-1971[PMID:25684965 DOI:10.3748/wjg.v21.i6.1956]
69 Mosli M,Croome K,Qumosani K,Al-Judaibi B,Beaton M,Marotta P,Chandok N.The effect of liver transplantation for primary sclerosing cholangitis on disease activity in patients with inflammatory bowel disease.Gastroenterol Hepatol(N Y)2013;9:434-441[PMID:23935552]
70 Mouchli MA,Singh S,Boardman L,Bruining DH,Lightner AL,Rosen CB,Heimbach JK,Hasan B,Poterucha JJ,Watt KD,Kane SV,Raffals LE,Loftus EV.Natural History of Established and De Novo Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis.Inflamm Bowel Dis 2018;24:1074-1081[PMID:29522202 DOI:10.1093/ibd/izx096]
71 Lindor KD,Wiesner RH,Colwell LJ,Steiner B,Beaver S,LaRusso NF.The combination of prednisone and colchicine in patients with primary sclerosing cholangitis.Am J Gastroenterol 1991;86:57-61[PMID:1986556]
72 van Hoogstraten HJ,Vleggaar FP,Boland GJ,van Steenbergen W,Griffioen P,Hop WC,van Hattum J,van Berge Henegouwen GP,Schalm SW,van Buuren HR.Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis:a randomized double-blind pilot study.BelgianDutch PSC Study Group.Am J Gastroenterol 2000;95:2015-2022[PMID:10950051 DOI:10.1111/j.1572-0241.2000.02267.x]
73 Angulo P,Batts KP,Jorgensen RA,LaRusso NA,Lindor KD.Oral budesonide in the treatment of primary sclerosing cholangitis.Am J Gastroenterol 2000;95:2333-2337[PMID:11007238 DOI:10.1111/j.1572-0241.2000.02323.x]
74 Knox TA,Kaplan MM.A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis.Gastroenterology 1994;106:494-499[PMID:8299916]
75 Lindor KD,Jorgensen RA,Anderson ML,Gores GJ,Hofmann AF,LaRusso NF.Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis:a pilot study.Am J Gastroenterol 1996;91:511-515[PMID:8633500]
76 Sterling RK,Salvatori JJ,Luketic VA,Sanyal AJ,Fulcher AS,Stravitz RT,Contos MJ,Mills AS,Shiffman ML.A prospective,randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis.Aliment Pharmacol Ther 2004;20:943-949[PMID:15521841 DOI:10.1111/j.1365-2036.2004.02214.x]
77 Talwalkar JA,Angulo P,Keach JC,Petz JL,Jorgensen RA,Lindor KD.Mycophenolate mofetil for the treatment of primary sclerosing cholangitis.Am J Gastroenterol 2005;100:308-312[PMID:15667487DOI:10.1111/j.1572-0241.2005.40484.x]
78 Van Thiel DH,Carroll P,Abu-Elmagd K,Rodriguez-Rilo H,Irish W,McMichael J,Starzl TE.Tacrolimus(FK 506),a treatment for primary sclerosing cholangitis:results of an open-label preliminary trial.Am J Gastroenterol 1995;90:455-459[PMID:7532912]
79 Hommes DW,Erkelens W,Ponsioen C,Stokkers P,Rauws E,van der Spek M,ten Kate F,van Deventer SJ.A double-blind,placebo-controlled,randomized study of infliximab in primary sclerosing cholangitis.J Clin Gastroenterol 2008;42:522-526[PMID:18344886 DOI:10.1097/MCG.0b013e3181662426]
80 Epstein MP,Kaplan MM.A pilot study of etanercept in the treatment of primary sclerosing cholangitis.Dig Dis Sci 2004;49:1-4[PMID:14992426]
81 Franceschet I,Cazzagon N,Del Ross T,D'IncàR,Buja A,Floreani A.Primary sclerosing cholangitis associated with inflammatory bowel disease:an observational study in a Southern Europe population focusing on new therapeutic options.Eur J Gastroenterol Hepatol 2016;28:508-513[PMID:26872110DOI:10.1097/MEG.0000000000000596]
82 Dubinsky MC,Cross RK,Sandborn WJ,Long M,Song X,Shi N,Ding Y,Eichner S,Pappalardo B,Ganguli A,Wang A.Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease.Inflamm Bowel Dis 2018[PMID:29668916 DOI:10.1093/ibd/izy065]
83 Gregorio GV,Portmann B,Karani J,Harrison P,Donaldson PT,Vergani D,Mieli-Vergani G.Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood:a 16-year prospective study.Hepatology 2001;33:544-553[PMID:11230733 DOI:10.1053/jhep.2001.22131]
84 Pallavicino F,Pellicano R,Reggiani S,Simondi D,Sguazzini C,Bonagura AG,CisaròF,Rizzetto M,Astegiano M.Inflammatory bowel diseases and primary sclerosing cholangitis:hepatic and pancreatic side effects due to azathioprine.Eur Rev Med Pharmacol Sci 2013;17:84-87[PMID:23329527]
85 Cardile S,Candusso M,Papadatou B,Bracci F,Knafelz D,Torre G.Lack of efficacy of infliximab in the treatment of primary sclerosing cholangitis in inflammatory bowel diseases in childhood.Eur JGastroenterol Hepatol 2017;29:736[PMID:28441268 DOI:10.1097/MEG.0000000000000847]
86 Ricciuto A,Fish J,Carman N,Walters TD,Church PC,Hansen BE,Crowley E,Siddiqui I,Nguyen GC,Kamath BM,Griffiths AM.Symptoms Do Not Correlate With Findings From Colonoscopy in Children With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.Clin Gastroenterol Hepatol 2018;16:1098-1105.e1[PMID:29378308 DOI:10.1016/j.cgh.2018.01.020]
87 BrooméU,L?fberg R,Lundqvist K,Veress B.Subclinical time span of inflammatory bowel disease in patients with primary sclerosing cholangitis.Dis Colon Rectum 1995;38:1301-1305[PMID:7497843]
88 Lazaridis KN,LaRusso NF.Primary Sclerosing Cholangitis.N Engl J Med 2016;375:2501-2502
89 Dlugosz A,Barakat AM,Bj?rkstr?m NK,?st?,Bergquist A.Diagnostic yield of endomicroscopy for dysplasia in primary sclerosing cholangitis associated inflammatory bowel disease:a feasibility study.Endosc Int Open 2016;4:E901-E911[PMID:27540581 DOI:10.1055/s-0042-111203]
90 Levy C.Evolving role of obeticholic acid in primary biliary cholangitis.Hepatology 2018;67:1666-1668[PMID:29222924 DOI:10.1002/hep.29726]
91 Miethke AG,Zhang W,Simmons J,Taylor AE,Shi T,Shanmukhappa SK,Karns R,White S,Jegga AG,Lages CS,Nkinin S,Keller BT,Setchell KD.Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice.Hepatology 2016;63:512-523[PMID:26172874 DOI:10.1002/hep.27973]
92 Assis DN,Abdelghany O,Cai SY,Gossard AA,Eaton JE,Keach JC,Deng Y,Setchell KD,Ciarleglio M,Lindor KD,Boyer JL.Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis:A Human Pilot Study.J Clin Gastroenterol 2017;51:e11-e16[PMID:27428727 DOI:10.1097/MCG.0000000000000591]
93 Friedman SL,Ratziu V,Harrison SA,Abdelmalek MF,Aithal GP,Caballeria J,Francque S,Farrell G,Kowdley KV,Craxi A,Simon K,Fischer L,Melchor-Khan L,Vest J,Wiens BL,Vig P,Seyedkazemi S,Goodman Z,Wong VW,Loomba R,Tacke F,Sanyal A,Lefebvre E.A randomized,placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.Hepatology 2018;67:1754-1767[PMID:28833331 DOI:10.1002/hep.29477]
94 Yu DC,Mennone A,Vig P,Boyer J.Cenicriviroc,a cytokine receptor antagonist,potentiated the effects of all-trans retinoic acid by reducing neutrophils and T cells in the liver of rodent cholestatic models.Hepatology 2017;66:938-939
95 Waye JD.Endoscopic retrograde cholangiopancreatography in the infant.Am J Gastroenterol 1976;65:461-463[PMID:949055]
96 Vegting IL,Tabbers MM,Taminiau JA,Aronson DC,Benninga MA,Rauws EA.Is endoscopic retrograde cholangiopancreatography valuable and safe in children of all ages?J Pediatr Gastroenterol Nutr 2009;48:66-71[PMID:19172126 DOI:10.1097/MPG.0b013e31817a24cf]
97 Rosen JD,Lane RS,Martinez JM,Perez EA,Tashiro J,Wagenaar AE,Van Haren RM,Kumar A,Sola JE.Success and safety of endoscopic retrograde cholangiopancreatography in children.J Pediatr Surg2017;52:1148-1151[PMID:28188033 DOI:10.1016/j.jpedsurg.2017.01.051]
98 Keane MG,Kumar M,Cieplik N,Thorburn D,Johnson GJ,Webster GJ,Chapman MH,Lindley KJ,Pereira SP.Paediatric pancreaticobiliary endoscopy:a 21-year experience from a tertiary hepatobiliary centre and systematic literature review.BMC Pediatr 2018;18:42[PMID:29426291 DOI:10.1186/s12887-017-0959-9]
99 Bonasso PC,Gurien LA,Staszak J,Gowen ME,Troendle DM,Odiase E,Lazar L,Ruan W,Barth BA,Williams RF,Dassinger MS.In-Hospital Pediatric ERCP is Associated with Shorter Hospitalization for Children with Choledocholithiasis.J Pediatr Gastroenterol Nutr 2018[PMID:30044307]
100 Troendle DM,Barth BA.ERCP can be safely and effectively performed by a pediatric gastroenterologist for choledocholithiasis in a pediatric facility.J Pediatr Gastroenterol Nutr 2013;57:655-658[PMID:24048163 DOI:10.1097/MPG.0000000000000124]
101 Lindor KD,Kowdley KV,Harrison ME;American College of Gastroenterology.ACG Clinical Guideline:Primary Sclerosing Cholangitis.Am J Gastroenterol 2015;110:646-59;quiz 660[PMID:25869391 DOI:10.1038/ajg.2015.112]
102 Stiehl A,Rudolph G,Kl?ters-Plachky P,Sauer P,Walker S.Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid:outcome after endoscopic treatment.J Hepatol 2002;36:151-156[PMID:11830325]
103 Kaya M,Petersen BT,Angulo P,Baron TH,Andrews JC,Gostout CJ,Lindor KD.Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis.Am J Gastroenterol 2001;96:1059-1066[PMID:11316147 DOI:10.1111/j.1572-0241.2001.03690.x]
104 Aabakken L,Karlsen TH,Albert J,Arvanitakis M,Chazouilleres O,Dumonceau JM,F?rkkil?M,Fickert P,Hirschfield GM,Laghi A,Marzioni M,Fernandez M,Pereira SP,Pohl J,Poley JW,Ponsioen CY,Schramm C,Swahn F,Tringali A,Hassan C.Role of endoscopy in primary sclerosing cholangitis:European Society of Gastrointestinal Endoscopy(ESGE)and European Association for the Study of the Liver(EASL)Clinical Guideline.Endoscopy 2017;49:588-608[PMID:28420030 DOI:10.1055/s-0043-107029]
105 Ponsioen CY,Arnelo U,Bergquist A,Rauws EA,Paulsen V,CantúP,Parzanese I,De Vries EM,van Munster KN,Said K,Chazouillères O,Desaint B,Kemgang A,F?rkkil?M,Van der Merwe S,Van Steenbergen W,Marschall HU,Stotzer PO,Thorburn D,Pereira SP,Aabakken L.No Superiority of Stents vs Balloon Dilatation for Dominant Strictures in Patients With Primary Sclerosing Cholangitis.Gastroenterology 2018;155:752-759.e5[PMID:29803836 DOI:10.1053/j.gastro.2018.05.034]
106 Liu R,Cox K,Guthery SL,Book L,Witt B,Chadwick B,Adler DG.Cholangiocarcinoma and high-grade dysplasia in young patients with primary sclerosing cholangitis.Dig Dis Sci 2014;59:2320-2324[PMID:24748183 DOI:10.1007/s10620-014-3152-0]
107 Njei B,McCarty TR,Varadarajulu S,Navaneethan U.Systematic review with meta-analysis:endoscopic retrograde cholangiopancreatography-based modalities for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis.Aliment Pharmacol Ther 2016;44:1139-1151[PMID:27696456 DOI:10.1111/apt.13817]
108 Barkin JA,Levy C,Souto EO.Endoscopic Management of Primary Sclerosing Cholangitis.Ann Hepatol2017;16:842-850[PMID:29055922 DOI:10.5604/01.3001.0010.5274]
109 Imani Fooladi AA,Mahmoodzadeh Hosseini H,Nourani MR,Khani S,Alavian SM.Probiotic as a novel treatment strategy against liver disease.Hepat Mon 2013;13:e7521[PMID:23610585 DOI:10.5812/hepatmon.7521]
110 Jones EA,Molenaar HA,Oosting J.Ondansetron and pruritus in chronic liver disease:a controlled study.Hepatogastroenterology 2007;54:1196-1199[PMID:17629069]
111 Neff GW,O'Brien CB,Reddy KR,Bergasa NV,Regev A,Molina E,Amaro R,Rodriguez MJ,Chase V,Jeffers L,Schiff E.Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease.Am J Gastroenterol 2002;97:2117-2119[PMID:12190187 DOI:10.1111/j.1572-0241.2002.05852.x]
112 Bolier AR,Peri S,Oude Elferink RP,Beuers U.The challenge of cholestatic pruritus.Acta Gastroenterol Belg 2012;75:399-404[PMID:23402082]
113 Reig A,SeséP,Parés A.Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.Am J Gastroenterol 2018;113:49-55[PMID:29016567 DOI:10.1038/ajg.2017.287]
114 Corpechot C,Chazouilleres O,Rousseau A.A 2-year multicenter,double-blind,randomized,placebocontrolled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate response to ursodeoxycholic acid therapy.Hepatology 2017;66
115 Ponsioen CY,Chapman RW,Chazouillères O,Hirschfield GM,Karlsen TH,Lohse AW,Pinzani M,Schrumpf E,Trauner M,Gores GJ.Surrogate endpoints for clinical trials in primary sclerosing cholangitis:Review and results from an International PSC Study Group consensus process.Hepatology 2016;63:1357-1367[PMID:26418478 DOI:10.1002/hep.28256]
116 Laboratories MM.Alkaline Phosphatase,Total and Isozymes,Serum:Clinical and Interpretive.Hepatology 2017;64:256-258
117 Turan S,Topcu B,G?k?e?,Güran T,Atay Z,Omar A,Ak?ay T,Bereket A.Serum alkaline phosphatase levels in healthy children and evaluation of alkaline phosphatase z-scores in different types of rickets.J Clin Res Pediatr Endocrinol 2011;3:7-11[PMID:21448327 DOI:10.4274/jcrpe.v3i1.02]
118 Otero JL,González-Peralta RP,Andres JM,Jolley CD,Novak DA,Haafiz A.Elevated Alkaline Phosphatase in Children:An Algorithm to Determine When a"Wait and See"Approach is Optimal.Clin Med Insights Pediatr 2011;5:15-18[PMID:23761996 DOI:10.4137/CMPed.S6872]
119 Vesterhus M,Hov JR,Holm A,Schrumpf E,Nyg?rd S,Godang K,Andersen IM,Naess S,Thorburn D,Saffioti F,Vatn M,Gilja OH,Lund-Johansen F,Syversveen T,Brabrand K,Parés A,Ponsioen CY,Pinzani M,F?rkkil?M,Moum B,Ueland T,R?sj?H,Rosenberg W,Boberg KM,Karlsen TH.Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis.Hepatology 2015;62:188-197[PMID:25833813 DOI:10.1002/hep.27825]
120 Serai SD,Trout AT,Miethke A,Diaz E,Xanthakos SA,Dillman JR.Putting it all together:established and emerging MRI techniques for detecting and measuring liver fibrosis.Pediatr Radiol 2018;48:1256-1272[PMID:30078038 DOI:10.1007/s00247-018-4083-2]
121 Goldberg D,French B,Thomasson A,Reddy KR,Halpern SD.Waitlist survival of patients with primary sclerosing cholangitis in the model for end-stage liver disease era.Liver Transpl 2011;17:1355-1363[PMID:21837735 DOI:10.1002/lt.22396]
122 Jossen J,Annunziato R,Kim HS,Chu J,Arnon R.Liver Transplantation for Children With Primary Sclerosing Cholangitis and Autoimmune Hepatitis:UNOS Database Analysis.J Pediatr Gastroenterol Nutr 2017;64:e83-e87[PMID:27755342 DOI:10.1097/MPG.0000000000001438]
123 Miloh T,Anand R,Yin W,Vos M,Kerkar N,Alonso E;Studies of Pediatric Liver Transplantation Research Group.Pediatric liver transplantation for primary sclerosing cholangitis.Liver Transpl 2011;17:925-933[PMID:21506253 DOI:10.1002/lt.22320]
124 Goldberg DS,French B,Thomasson A,Reddy KR,Halpern SD.Current trends in living donor liver transplantation for primary sclerosing cholangitis.Transplantation 2011;91:1148-1152[PMID:21544035DOI:10.1097/TP.0b013e31821694b3]
125 Deneau MR,Amin M,Amir AZ,Auth M,Bazerbachi F,Broderick A,El-Youssef M,Ferrari F,Furuya KN,Gottrand F,Gupta N,Homan M,Kamath BM,Lin H,Mo Kim K,Kolho KL,Konidari A,Koot B,Iorio R,Jensen MK,Mack C,Martinez M,Ricciuto A,Smolka V,Tanaka A,Valentino PL,Venkat V,Vitola B,Vos MB,Woynarowski M,Yap J,Miloh T.MELD score and liver transplantation in children with primary sclerosing cholangitis.Pediatric Gastroenterology Nutrition 2018;67
126 Hoffmann K,Hinz U,Hillebrand N,Ganten T,Gotthardt D,Longerich T,Schirmacher P,Schemmer P.The MELD score predicts the short-term and overall survival after liver transplantation in patients with primary sclerosing cholangitis or autoimmune liver diseases.Langenbecks Arch Surg 2014;399:1001-1009[PMID:25106131 DOI:10.1007/s00423-014-1237-z]
127 Darwish Murad S,Kim WR,Harnois DM,Douglas DD,Burton J,Kulik LM,Botha JF,Mezrich JD,Chapman WC,Schwartz JJ,Hong JC,Emond JC,Jeon H,Rosen CB,Gores GJ,Heimbach JK.Efficacy of neoadjuvant chemoradiation,followed by liver transplantation,for perihilar cholangiocarcinoma at 12 UScenters.Gastroenterology 2012;143:88-98.e3;quiz e14[PMID:22504095 DOI:10.1053/j.gastro.2012.04.008]
128 J?rgensen KK,Lindstr?m L,Cvancarova M,Karlsen TH,Castedal M,Friman S,Schrumpf E,Foss A,Isoniemi H,Nordin A,Holte K,Rasmussen A,Bergquist A,Vatn MH,Boberg KM.Immunosuppression after liver transplantation for primary sclerosing cholangitis influences activity of inflammatory bowel disease.Clin Gastroenterol Hepatol 2013;11:517-523[PMID:23333218 DOI:10.1016/j.cgh.2012.12.027]
129 Verdonk RC,Dijkstra G,Haagsma EB,Shostrom VK,Van den Berg AP,Kleibeuker JH,Langnas AN,Sudan DL.Inflammatory bowel disease after liver transplantation:risk factors for recurrence and de novo disease.Am J Transplant 2006;6:1422-1429[PMID:16686766 DOI:10.1111/j.1600-6143.2006.01333.x]
130 Buchholz BM,Lykoudis PM,Ravikumar R,Pollok JM,Fusai GK.Role of colectomy in preventing recurrent primary sclerosing cholangitis in liver transplant recipients.World J Gastroenterol 2018;24:3171-3180[PMID:30065563 DOI:10.3748/wjg.v24.i28.3171]
131 Goldberg DS,French B,Abt PL,Olthoff K,Shaked A.Superior survival using living donors and donorrecipient matching using a novel living donor risk index.Hepatology 2014;60:1717-1726[PMID:25042283 DOI:10.1002/hep.27307]
132 Wells MM,Croome KP,Boyce E,Chandok N.Roux-en-Y choledochojejunostomy versus duct-to-duct biliary anastomosis in liver transplantation for primary sclerosing cholangitis:a meta-analysis.Transplant Proc 2013;45:2263-2271[PMID:23953538 DOI:10.1016/j.transproceed.2013.01.066]
133 Bezinover D,Iskandarani K,Chinchilli V,McQuillan P,Saner F,Kadry Z,Riley TR,Janicki PK.Autoimmune conditions are associated with perioperative thrombotic complications in liver transplant recipients:A UNOS database analysis.BMC Anesthesiol 2016;16:26[PMID:27207434 DOI:10.1186/s12871-016-0192-3]
134 Montano-Loza AJ,Bhanji RA,Wasilenko S,Mason AL.Systematic review:recurrent autoimmune liver diseases after liver transplantation.Aliment Pharmacol Ther 2017;45:485-500[PMID:27957759 DOI:10.1111/apt.13894]
135 Deneau MR,El-Matary W,Valentino PL,Abdou R,Alqoaer K,Amin M,Amir AZ,Auth M,Bazerbachi F,Broderick A,Chan A,Cotter J,Doan S,El-Youssef M,Ferrari F,Furuya KN,Gottrand M,Gottrand F,Gupta N,Homan M,Kamath BM,Mo Kim K,Kolho KL,Konidari A,Koot B,Iorio R,Ledder O,Mack C,Martinez M,Miloh T,Mohan P,O'Cathain N,Papadopoulou A,Ricciuto A,Saubermann L,Sathya P,Shteyer E,Smolka V,Tanaka A,Varier R,Venkat V,Vitola B,Vos MB,Woynarowski M,Yap J,Jensen MK.Recurrence of primary sclerosing cholangitis after liver transplantation in children:data from the Pediatric PSC Consortium.Hepatology 2017;66:S76
136 Soufi N,Bazerbachi F,Deneau M.Post-Transplant Disease Recurrence in Pediatric PSC.Curr Gastroenterol Rep 2018;20:44[PMID:30083892 DOI:10.1007/s11894-018-0649-2]
137 Yamada Y,Hoshino K,Fuchimoto Y,Matsubara K,Hibi T,Yagi H,Abe Y,Shinoda M,Kitago M,Obara H,Yagi T,Okajima H,Kaido T,Uemoto S,Suzuki T,Kubota K,Yoshizumi T,Maehara Y,Inomata Y,Kitagawa Y,Egawa H,Kuroda T.Rituximab Induction to Prevent the Recurrence of PSC After Liver Transplantation-The Lessons Learned From ABO-Incompatible Living Donor Liver Transplantation.Transplant Direct 2018;4:e342[PMID:29464203 DOI:10.1097/TXD.0000000000000760]
138 Singh S,Edakkanambeth Varayil J,Loftus EV,Talwalkar JA.Incidence of colorectal cancer after liver transplantation for primary sclerosing cholangitis:a systematic review and meta-analysis.Liver Transpl2013;19:1361-1369[PMID:24019127 DOI:10.1002/lt.23741]
139 Altwegg R,Combes R,Laharie D,De Ledinghen V,Radenne S,Conti F,Chazouilleres O,Duvoux C,Dumortier J,Leroy V,Treton X,Durand F,Dharancy S,Nachury M,Goutorbe F,Lamblin G,Boivineau L,Peyrin-Biroulet L,Pageaux GP.Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis:A nationwide case series.Dig Liver Dis 2018;50:668-674[PMID:29655972 DOI:10.1016/j.dld.2018.02.014]
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |